The Prevacus Story
Spun out of Florida State University, Prevacus is a development stage company focusing on a new treatment for concussions, a.k.a., mild traumatic brain injuries or mTBI. TBI touches many lives and is a major cause of disability worldwide. Particularly vulnerable are athletes, the military, the elderly and victims of motor vehicle accidents.
Currently, there are no drugs available for concussion treatment – just rehabilitation and rest. Prevacus’ founder, Jacob VanLandingham is a Ph.D., who worked in the Department of Biomedical Sciences for the FSU College of Medicine, has spent many years in the laboratory analyzing the positive effects neuro-steroids have on edema – swelling of the brain. However, the sexual and clotting side effects of some neuro-steroids limit their use. The Prevacus scientific team is in the process of developing an alternate line of concussion therapies and is currently evaluating the safety and efficacy of these drugs in preparation for bringing these products to market. Further, Prevacus is in the early stages of novel drug testing in animals for other neurodegenerative disorders, including Alzheimer’s disease.